Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) is expected to report Q2 2025 earnings around August 4, with consensus estimates forecasting a $0.13 per share loss, an 85.7% year-over-year decline, despite projected revenue of $84.64 million, up 15.6%. Analysts have recently lowered EPS estimates by 6.25%. A negative Zacks Earnings ESP of -6.18% combined with a Zacks Rank of #4 indicates the company is unlikely to beat consensus EPS, suggesting it is not a compelling earnings-beat candidate.

Analysis

Ardelyx (ARDX) presents a challenging outlook ahead of its Q2 2025 earnings release, characterized by a significant divergence between top-line growth and bottom-line profitability. While revenues are projected to increase by a healthy 15.6% year-over-year to $84.64 million, consensus estimates forecast a loss of $0.13 per share, marking a stark 85.7% decline in earnings from the prior year. Bearish sentiment is reinforced by recent analyst activity, with the consensus EPS estimate having been revised downward by 6.25% over the last 30 days. Predictive indicators are also negative; the company holds a Zacks Rank of #4 (Sell) and a negative Earnings ESP of -6.18%, a combination that suggests a low probability of a positive earnings surprise. This is further contextualized by a poor recent history, including a -70% earnings surprise miss last quarter and a record of beating estimates in only two of the past four quarters. The weakness appears company-specific when contrasted with industry peer United Therapeutics (UTHR), which exhibits positive growth forecasts for both revenue (+11.3%) and earnings (+16.2%) and a positive Earnings ESP, indicating a higher likelihood of an earnings beat.

Key Decisions for Investors

• Given the negative analyst revisions, a Zacks #4 (Sell) rating, and a negative Earnings ESP of -6.18%, investors should exercise significant caution, as the quantitative indicators suggest Ardelyx is not a compelling earnings-beat candidate.
• The primary focus during the August 4th earnings call should be on management's explanation for the severe margin contraction, specifically why a 15.6% revenue increase is expected to result in an 85.7% drop in earnings.
• Investors should monitor for any forward-looking guidance or unforeseen catalysts that could potentially offset the widely anticipated weak quarterly results, as these factors will likely determine the stock's trajectory post-announcement.
• The starkly contrasting outlooks for Ardelyx and industry peer United Therapeutics could present a potential pairs-trading opportunity for investors looking to hedge sector exposure or capitalize on perceived relative mispricing.